Clinical Trials: SEARCH[STUDY] TILT[STUDY:STUDY-FIRST-POSTED] ( Pancytopenia [STUDY:DISEASE] )
#
NCTID/Status
Study
Last Changed
1
NCT03521947
Not yet recruiting
Not yet recruiting
May 9, 2018
2
NCT00001214
Completed
Completed
Collection of Blood From Patients With Pancytopenia
Conditions: Pancytopenia
Conditions: Pancytopenia
August 8, 2019
3
NCT02928991
Recruiting
Recruiting
Fludarabine Based RIC for Bone Marrow Failure Syndromes
Conditions: Bone Marrow Failure Syndromes
Intervention: MRD-BMT With Fludarabine-based RIC For Acquired AA, MRD-BMT With Fludarabine-based RIC For IBMF With Trilineage Aplasia, MRD-BMT With Fludarabine-based RIC For IBMF Without Trilineage Aplasia
Conditions: Bone Marrow Failure Syndromes
Intervention: MRD-BMT With Fludarabine-based RIC For Acquired AA, MRD-BMT With Fludarabine-based RIC For IBMF With Trilineage Aplasia, MRD-BMT With Fludarabine-based RIC For IBMF Without Trilineage Aplasia
January 8, 2019
4
NCT02314273
Completed
Completed
Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL
Conditions: Pancytopenia Due to Chemotherapy
Intervention: RhIL-11
Conditions: Pancytopenia Due to Chemotherapy
Intervention: RhIL-11
December 8, 2014
5
NCT02958462
Recruiting
Recruiting
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Conditions: Myeloid Malignancy; Inherited Bone Marrow Failure Syndrome; Clonal Expansion; Cytopenia
Intervention: Follow Up
Conditions: Myeloid Malignancy; Inherited Bone Marrow Failure Syndrome; Clonal Expansion; Cytopenia
Intervention: Follow Up
January 7, 2019
6
NCT00774527
Completed
Completed
Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT
Conditions: Bone Marrow Failure Syndromes
Intervention: Cyclophosphamide-fludarabine-anti Thymocyte Globulin
Conditions: Bone Marrow Failure Syndromes
Intervention: Cyclophosphamide-fludarabine-anti Thymocyte Globulin
February 16, 2011
7
NCT00001398
Completed
Completed
Stem Cell Factor Medication for Aplastic Anemia
Conditions: Aplastic Anemia; Pancytopenia
Intervention: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
Conditions: Aplastic Anemia; Pancytopenia
Intervention: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
March 3, 2008
8
NCT00085670
Completed
Completed
Cytokine Gene Polymorphisms in Bone Marrow Failure
Conditions: Bone Marrow Diseases
Conditions: Bone Marrow Diseases
September 21, 2018
9
NCT00001399
Completed
Completed
Gene Therapy for the Treatment of Fanconi's Anemia Type C
Conditions: Fanconi's Anemia; Pancytopenia
Intervention: Transduced CD34+ Cells
Conditions: Fanconi's Anemia; Pancytopenia
Intervention: Transduced CD34+ Cells
June 30, 2017
10
NCT02393508
Unknown status
Unknown status
The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population
Conditions: Bone Marrow Failure Syndrome
Intervention: Fresh Human Red Blood Cells, Aged Human Red Blood Cells
Conditions: Bone Marrow Failure Syndrome
Intervention: Fresh Human Red Blood Cells, Aged Human Red Blood Cells
December 19, 2015
11
NCT01856582
Terminated
Terminated
CD34+ Stem Cell Infusion to Augment Graft Function
Conditions: Waning Donor Chimerism; Waning Immune Function; Primary Immunodeficiency Disease(s); Bone Marrow Failure
Intervention: CD34+
Conditions: Waning Donor Chimerism; Waning Immune Function; Primary Immunodeficiency Disease(s); Bone Marrow Failure
Intervention: CD34+
December 18, 2018
12
NCT02224872
Recruiting
Recruiting
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia; Bone Marrow Failure Syndromes
Intervention: Bone Marrow Transplant, Thymoglobulin, Fludarabine, Cyclophosphamide, TBI, Mesna, Tacrolimus, Mycophenolic Acid Mofetil
Conditions: Severe Aplastic Anemia; Bone Marrow Failure Syndromes
Intervention: Bone Marrow Transplant, Thymoglobulin, Fludarabine, Cyclophosphamide, TBI, Mesna, Tacrolimus, Mycophenolic Acid Mofetil
December 18, 2018
13
NCT03460301
Active, not recruiting
Active, not recruiting
Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
Conditions: PNH
Conditions: PNH
March 4, 2018
14
NCT00027274
Recruiting
Recruiting
Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Diamond Blackfan Anemia; Dyskeratosis Congenita; Fanconi Anemia; Shwachman Diamond Syndrome; Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Conditions: Diamond Blackfan Anemia; Dyskeratosis Congenita; Fanconi Anemia; Shwachman Diamond Syndrome; Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
June 14, 2019
15
NCT00038779
Terminated
Terminated
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Conditions: Leukemia; Non Hodgkin's Lymphoma; Aplastic Anemia
Intervention: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Conditions: Leukemia; Non Hodgkin's Lymphoma; Aplastic Anemia
Intervention: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
October 29, 2018
16
NCT03773393
Recruiting
Recruiting
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
Conditions: Bone Marrow Disease
Intervention: CK0801
Conditions: Bone Marrow Disease
Intervention: CK0801
June 3, 2019
17
NCT01760096
Unknown status
Unknown status
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
Conditions: Paroxysmal Nocturnal Hemoglobinuria; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Proteinuria; Urination Disorders; Thrombosis; Bone Marrow Failure; Aplastic Anemia,; Anemia, Hemolytic
Intervention: Levamisole+cyclosporin A+Glucocorticoids, Cyclosporin A+Glucocorticoids, Glucocorticoids
Conditions: Paroxysmal Nocturnal Hemoglobinuria; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Proteinuria; Urination Disorders; Thrombosis; Bone Marrow Failure; Aplastic Anemia,; Anemia, Hemolytic
Intervention: Levamisole+cyclosporin A+Glucocorticoids, Cyclosporin A+Glucocorticoids, Glucocorticoids
January 1, 2013
18
NCT03047746
Recruiting
Recruiting
Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF
Conditions: Acquired Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Inherited Bone Marrow Failure Syndromes
Intervention: CliniMACs
Conditions: Acquired Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Inherited Bone Marrow Failure Syndromes
Intervention: CliniMACs
December 18, 2018
19
NCT03249129
Not yet recruiting
Not yet recruiting
Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Conditions: Bone Marrow Failure; Trauma
Conditions: Bone Marrow Failure; Trauma
May 15, 2018
20
NCT00315419
Unknown status
Unknown status
Identifying Characteristics of Bone Marrow Failure Syndromes
Conditions: Bone Marrow Failure Syndromes; Anemia, Aplastic; Myelodysplastic Syndromes; Hemoglobinuria, Paroxysmal; Red-Cell Aplasia, Pure; Purpura, Thrombocytopenic; Leukemia, Lymphocytic
Conditions: Bone Marrow Failure Syndromes; Anemia, Aplastic; Myelodysplastic Syndromes; Hemoglobinuria, Paroxysmal; Red-Cell Aplasia, Pure; Purpura, Thrombocytopenic; Leukemia, Lymphocytic
April 19, 2010
21
NCT01757145
Unknown status
Unknown status
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome
Intervention: Eltrombopag
Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome
Intervention: Eltrombopag
June 18, 2015
22
NCT00176878
Completed
Completed
Stem Cell Transplant for Bone Marrow Failure Syndromes
Conditions: Diamond-Blackfan Anemia; Kostmann's Neutropenia; Shwachman-Diamond Syndrome
Intervention: Stem Cell Transplant, Fludarabine Monophosphate, Total Lymphoid Irradiation, Busulfan, Anti-thymocyte Globulin
Conditions: Diamond-Blackfan Anemia; Kostmann's Neutropenia; Shwachman-Diamond Syndrome
Intervention: Stem Cell Transplant, Fludarabine Monophosphate, Total Lymphoid Irradiation, Busulfan, Anti-thymocyte Globulin
December 3, 2017
23
NCT01192425
Completed
Completed
Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Conditions: Hemoglobinuria
Conditions: Hemoglobinuria
August 31, 2010
24
NCT00228813
Terminated
Terminated
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
Conditions: Hematologic Malignancies
Intervention: Granulocyte Colony Stimulating Factor
Conditions: Hematologic Malignancies
Intervention: Granulocyte Colony Stimulating Factor
August 10, 2017
25
NCT01328587
Active, not recruiting
Active, not recruiting
Eltrombopag for Moderate Aplastic Anemia
Conditions: Moderate Aplastic Anemia; Unilineage Bone Marrow Failure Disorders
Intervention: Eltrombopag
Conditions: Moderate Aplastic Anemia; Unilineage Bone Marrow Failure Disorders
Intervention: Eltrombopag
March 29, 2019
26
NCT03500731
Recruiting
Recruiting
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Conditions: Idiopathic Pulmonary Fibrosis; Emphysema or COPD
Intervention: CD3/CD19 Negative Hematopoietic Stem Cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Conditions: Idiopathic Pulmonary Fibrosis; Emphysema or COPD
Intervention: CD3/CD19 Negative Hematopoietic Stem Cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
April 3, 2019
27
NCT01071226
Active, not recruiting
Active, not recruiting
Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device
Conditions: Malignant Diseases (ie, Leukemia, MDS, Lymphoma); Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)
Intervention: CliniMACS (CD+3, CD+19 Depletion), CliniMACS (CD 34+ Positive Selection), HSCT
Conditions: Malignant Diseases (ie, Leukemia, MDS, Lymphoma); Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)
Intervention: CliniMACS (CD+3, CD+19 Depletion), CliniMACS (CD 34+ Positive Selection), HSCT
July 23, 2019
28
NCT00897260
Completed
Completed
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome
Intervention: Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders, Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders, Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome
Intervention: Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders, Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders, Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
January 24, 2018
29
NCT00731328
Completed
Completed
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia; Myelodysplastic Syndromes; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Leukemia; Myelodysplastic Syndromes; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
December 29, 2015
30
NCT01174108
Recruiting
Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia; MDS (Myelodysplastic Syndrome)
Intervention: Miltenyi CD34 Reagent System, Donor Derived G-CSF Mobilized PBC
Conditions: Severe Aplastic Anemia; MDS (Myelodysplastic Syndrome)
Intervention: Miltenyi CD34 Reagent System, Donor Derived G-CSF Mobilized PBC
May 23, 2019
31
NCT00004143
Completed
Completed
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Conditions: Sickle Cell Anemia; Severe Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria (PNH); Pure Red Cell Aplasia
Intervention: Campath, Chemo And/or TBI Allo SCT
Conditions: Sickle Cell Anemia; Severe Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria (PNH); Pure Red Cell Aplasia
Intervention: Campath, Chemo And/or TBI Allo SCT
November 19, 2014
32
NCT03145545
Available
Available
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Conditions: Leukemia; Bone Marrow Failure Syndrome; Immunodeficiencies
Intervention: Apha/beta T And CD19+ Cell Depletion Using CliniMACS Device
Conditions: Leukemia; Bone Marrow Failure Syndrome; Immunodeficiencies
Intervention: Apha/beta T And CD19+ Cell Depletion Using CliniMACS Device
June 12, 2019
33
NCT01193283
Completed
Completed
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
Conditions: Aplastic Anemia; Neutropenia; Pancytopenia; Severe Aplastic Anemia
Intervention: Cyclophosphamide, Cyclosporine
Conditions: Aplastic Anemia; Neutropenia; Pancytopenia; Severe Aplastic Anemia
Intervention: Cyclophosphamide, Cyclosporine
April 11, 2017
34
NCT01187017
Completed
Completed
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Conditions: Aplastic Anemia; Neutropenia; Pancytopenia; Severe Aplastic Anemia
Intervention: Cyclophosphamide, Fludarabine
Conditions: Aplastic Anemia; Neutropenia; Pancytopenia; Severe Aplastic Anemia
Intervention: Cyclophosphamide, Fludarabine
February 3, 2016
35
NCT00000597
Completed
Completed
Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
Conditions: Anemia, Aplastic; Hematologic Diseases; Pancytopenia; Blood Disease
Intervention: Antilymphocyte Serum, Nandrolone
Conditions: Anemia, Aplastic; Hematologic Diseases; Pancytopenia; Blood Disease
Intervention: Antilymphocyte Serum, Nandrolone
November 25, 2013
36
NCT02833805
Recruiting
Recruiting
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia; Aplastic Anemia; Bone Marrow Failure; Immunosuppression
Intervention: Thymoglobulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, Tacrolimus, Mycophenolate Mofetil
Conditions: Severe Aplastic Anemia; Aplastic Anemia; Bone Marrow Failure; Immunosuppression
Intervention: Thymoglobulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, Tacrolimus, Mycophenolate Mofetil
July 15, 2019
37
NCT02277639
Completed
Completed
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Conditions: Bone Marrow Failure Syndromes; Immunodeficiencies; Immune Dysregulation Syndromes
Intervention: CliniMACs Device
Conditions: Bone Marrow Failure Syndromes; Immunodeficiencies; Immune Dysregulation Syndromes
Intervention: CliniMACs Device
March 16, 2018
38
NCT00260689
Completed
Completed
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Conditions: Immunosuppresion; Thrombocytopenia; Pancytopenia; Neutropenia
Intervention: Anti-thymocyte Globulin (rabbit), Anti-thymocyte Globulin (horse), Cyclosporine, Alemtuzumab
Conditions: Immunosuppresion; Thrombocytopenia; Pancytopenia; Neutropenia
Intervention: Anti-thymocyte Globulin (rabbit), Anti-thymocyte Globulin (horse), Cyclosporine, Alemtuzumab
May 16, 2017
39
NCT01019876
Unknown status
Unknown status
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Conditions: Bone Marrow Failure; Osteopetrosis; Fanconi Anemia; Severe Combined Immunodeficiency
Intervention: Fludarabine, Cyclophosphamide, Cyclophosphamide 40, Cyclophosphamide 30
Conditions: Bone Marrow Failure; Osteopetrosis; Fanconi Anemia; Severe Combined Immunodeficiency
Intervention: Fludarabine, Cyclophosphamide, Cyclophosphamide 40, Cyclophosphamide 30
October 18, 2011
40
NCT02781155
Unknown status
Unknown status
Limiting Chemotherapy Side Effects by Using Moxa
Conditions: Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Toxicity Due to Chemotherapy
Intervention: Moxibustion
Conditions: Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Toxicity Due to Chemotherapy
Intervention: Moxibustion
May 19, 2016
41
NCT00065260
Completed
Completed
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Conditions: Aplastic Anemia
Intervention: Campath-1H, R-ATG, CsA
Conditions: Aplastic Anemia
Intervention: Campath-1H, R-ATG, CsA
February 3, 2016
42
NCT02055456
Unknown status
Unknown status
Nandrolone Decanoate in the Treatment of Telomeropathies
Conditions: Aplastic Anemia; Bone Marrow Failure Syndromes; Idiopathic Pulmonary Fibrosis; Telomere Shortening
Intervention: Nandrolone Decanoate
Conditions: Aplastic Anemia; Bone Marrow Failure Syndromes; Idiopathic Pulmonary Fibrosis; Telomere Shortening
Intervention: Nandrolone Decanoate
December 1, 2015
43
NCT02349906
Recruiting
Recruiting
Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
Conditions: Primary Immunodeficiencies; Inborn Errors of Metabolism; Haemoglobinopathies; Bone Marrow Failure Syndromes
Intervention: Treosulfan, Busilvex
Conditions: Primary Immunodeficiencies; Inborn Errors of Metabolism; Haemoglobinopathies; Bone Marrow Failure Syndromes
Intervention: Treosulfan, Busilvex
August 15, 2018
44
NCT01659606
Recruiting
Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita; Hoyeraal Hreidarsson Syndrome; Revesz Syndrome; Aplastic Anemia
Intervention: Alemtuzumab, Fludarabine, Cyclosporins, Mycophenolate Mofetil
Conditions: Dyskeratosis Congenita; Hoyeraal Hreidarsson Syndrome; Revesz Syndrome; Aplastic Anemia
Intervention: Alemtuzumab, Fludarabine, Cyclosporins, Mycophenolate Mofetil
April 2, 2019
45
NCT00006127
Unknown status
Unknown status
Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia
Conditions: Fanconi's Anemia
Intervention: Amifostine
Conditions: Fanconi's Anemia
Intervention: Amifostine
June 23, 2005
46
NCT00856388
Active, not recruiting
Active, not recruiting
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Fanconi Anemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenström Macroglobulinemia
Intervention: Fludarabine Phosphate, Melphalan, Total-body Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-thymocyte Globulin
Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Fanconi Anemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenström Macroglobulinemia
Intervention: Fludarabine Phosphate, Melphalan, Total-body Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-thymocyte Globulin
December 3, 2018
47
NCT00001962
Terminated
Terminated
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia; Pure Red Cell Aplasia; Diamond Blackfan Anemia
Intervention: Daclizumab
Conditions: Aplastic Anemia; Pure Red Cell Aplasia; Diamond Blackfan Anemia
Intervention: Daclizumab
April 28, 2015
48
NCT00004787
Completed
Completed
Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
Conditions: Shwachman Syndrome; Fanconi's Anemia; Dyskeratosis Congenita; Thrombocytopenia
Intervention: Filgrastim
Conditions: Shwachman Syndrome; Fanconi's Anemia; Dyskeratosis Congenita; Thrombocytopenia
Intervention: Filgrastim
June 23, 2005
49
NCT00755040
Completed
Completed
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Cyclosporine Ophthalmic Emulsion, Placebo
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Cyclosporine Ophthalmic Emulsion, Placebo
January 24, 2017
50
NCT00295971
Completed
Completed
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease
Conditions: Congenital Amegakaryocytic Thrombocytopenia; Leukemia; Myelodysplastic Syndromes; Severe Congenital Neutropenia
Intervention: Anti-thymocyte Globulin, Therapeutic Allogeneic Lymphocytes, Fludarabine Phosphate, Thiotepa, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, In Vitro-treated Peripheral Blood Stem Cell Transplantation, Total-body Irradiation
Conditions: Congenital Amegakaryocytic Thrombocytopenia; Leukemia; Myelodysplastic Syndromes; Severe Congenital Neutropenia
Intervention: Anti-thymocyte Globulin, Therapeutic Allogeneic Lymphocytes, Fludarabine Phosphate, Thiotepa, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, In Vitro-treated Peripheral Blood Stem Cell Transplantation, Total-body Irradiation
November 8, 2012
Last Updated
The last updated date is the most recent date when changes to a clinical trial were
submitted to ClinicalTrials.gov. There is often a delay of a few days before the
updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted
to ClinicalTrials.gov. There is often a delay of a few days before the
trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Safety Issue
If selected, restricts search results to those studies which have
an outcome measure designated as a safety issue. Note that this is a
poor estimate of the safety of a treatment or intervention, but it is
all we have now.
Funded By
Studies are supported by one or more organizations called sponsors.
Support includes contributions of facilities, expertise, and/or financial resources.
All sponsors in the database have been assigned one of the following organization types:
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Study Phase
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Age Group
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Gender
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility
name (such as the Mayo Clinic), enter it as a location term. Not all studies
include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency,
or organization sponsoring the trial. In addition, clinical trials assigns a
unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit.
Use this box to search for a trial by NCT identifier or any other study
identification numbers.
Examples:
Examples:
NCT00001789
97-h-0197
ia0006
actg 076
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is
conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are
conducting or otherwise supporting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Outcome Measures
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Outcome measures are used to evaluate trial results. For example, an obesity treatment
might be evaluated by a measure of weight loss after 6 months. Measures can also be used
to quantify side effects, such as number of myocardial infarctions,
number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Interventions
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Conditions
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Study Type
There are three types of studies available in ClinicalTrials.gov:
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Observational:
Expanded Access:
Studies where individuals are assigned to receive specific interventions.
Participants may receive diagnostic, therapeutic or other types of interventions.
Assignment of the intervention may or may not be random.
Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention.
Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals.
Participants may receive diagnostic, therapeutic, or other interventions, but the investigator
does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who
are failing on currently available treatments for their condition and also are unable to
participate in ongoing clinical trials. Expanded Access records are used to register all
types of non-protocol access to experimental treatments, including protocol exception,
single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Study Results
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Search Terms
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies.
These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Advanced Search:
Many searches are a single term and can be performed with a few words in the
search box. But, sometimes you need more control. Click on the Advanced Search tab
(if starting a new search) or Refine Search tab (if modifying an existing search)
to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Recruitment:
Interventions:
Outcomes Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
Country/State:
Location Terms:
Gender:
Age Group:
Phase:
Funded By:
Safety Issue:
First Received:
Last Updated:
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Performs a general search in all sections of the study record, including title,
description, conditions, interventions, locations, etc. Terms in this field are
searched the same as Basic Search.
Recruitment:
Limits search results to studies that are open or closed. New volunteers may be
able to participate in open studies, but not closed studies.
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Study Results:Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Values are color coded (as shown) in the search results.
Limits search results based on whether the study has results or not:
Study Type:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov.
Only a few studies have results available.Studies With Results, or
Studies Without Results
Limits search results to any of the following study types:
Conditions:
Interventional,
Observational, or
Expanded Access
Observational, or
Expanded Access
Performs a search on fields describing the diseases or conditions being studied.
Interventions:
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Sponsor/Collaborators:
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor (Lead):
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Study IDs:
Performs a search on fields listing ID numbers.
Country/State:
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state (e.g., United States, Alabama).
Location Terms:
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic).
Not all studies include this level of detail, but if they do, this will find them.
Gender:
Limits search results to those studies that accept female or male participants.
Age Group:
Limits search results to those studies that include at least one of the specified age
ranges. More than one age group can be selected.
Phase:
Limits search results to studies that are labeled with at least one of the specified
phases. More than one Phase can be selected.
Funded By:
Limits search results to studies that have at least one sponsor of the specified types.
More than one sponsor type can be selected.
Safety Issue:
Limits search results to studies that have at least one outcome measure designated as a safety issue.
First Received:
Limits search results to studies that were received by clinical trials within a
specified date range. The "From" or "To" field can be left blank.
Last Updated:
Limits search results to studies that were modified within a
specified date range. The "From" or "To" field can be left blank.
Refine Search:
Searches display a list of studies found (List Results tab). If you are not content with
the search results, click on the Refine Search tab at the top of the list to modify your
search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
When you are done making changes, click Search to display the new results.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
For example:
prostate cancer AND radiation
heart disease AND stroke AND California
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Aspirin OR ibuprofen
heart disease OR heart attack
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.